Glucose

Studies Show Diabetes Medicine Can Cause Urologic Complications

Retrieved on: 
söndag, maj 5, 2024
Urine, Risk, American Urological Association, Abstract (summary), Abstract, MD, Research, Attention, Patient, Kidney, Albany Medical Center, Cardiovascular disease, Glucose, Annual general meeting, Chronic kidney disease, Urinary tract infection, SAN, Heart failure, Pharmaceutical industry

Researchers will present their study findings covering important updates on diabetes medicine and urologic complications in San Antonio, Texas, from May 3 to 6.

Key Points: 
  • Researchers will present their study findings covering important updates on diabetes medicine and urologic complications in San Antonio, Texas, from May 3 to 6.
  • “These meds are increasingly popular due to their ability to lower cardiovascular events and the risk of end stage renal disease.
  • They are now first line therapies for diabetes management in patients with cardiovascular disease, chronic kidney disease and heart failure,” said Dr. Inouye.
  • All three of these talks discuss the urologic sequelae we see in our clinics.”
    The following abstracts are covered in the moderated panel:

Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer

Retrieved on: 
fredag, maj 3, 2024
Cell, National Cancer Institute, Macrophage, Sapienza University of Rome, Genome, Glucose, Wistar Institute, Gene, Brain, Tumor microenvironment, Wistar, Metabolomics, Neuroscience, Immunity, Ben, Medical research, Microglia, Research, Proteomics, Immunology, Histone, Malignancy, Gene expression, Neoplasm, Aurelia, Cancer, Collaborative writing, DSM-IV codes, Prognosis, Immunosuppression, Immunotherapy, Duke School, Disease, GLUT1, Patient, Metabolism, Immune system, Angelica, Vaccine

The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.

Key Points: 
  • The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.
  • Indeed, monocyte-derived macrophages, but not microglia, blocked the activity of T cells (immune cells that destroy tumor cells), in preclinical models and patients.
  • Glioblastoma is inherently dangerous due to its location in the brain and its immunosuppressive tumor microenvironment, which renders glioblastoma resistant to promising immunotherapies.
  • Note: The work detailed in this publication was initiated at The H. Lee Moffitt Cancer Center during Dr. Veglia’s time there and continued at Wistar.

Green Plains Reports First Quarter 2024 Financial Results

Retrieved on: 
fredag, maj 3, 2024
Alternative Energy, Energy, Agriculture, Natural Resources, Sequence, Glucose, Negotiation, Gasoline, Yeast, Aviation biofuel, Food safety, Enzyme, Mergers and acquisitions, Partner, Policy, Natural gas, Depreciation, Partnership, Biopolymer, Transport, Carbon, Ethanol, Plant, Obion, Tennessee, JV, Eye, Corn oil, Acquisition, Food, Marketing, Becker

Green Plains Inc. (NASDAQ:GPRE) (“Green Plains” or the “company”) today announced financial results for the first quarter of 2024.

Key Points: 
  • Green Plains Inc. (NASDAQ:GPRE) (“Green Plains” or the “company”) today announced financial results for the first quarter of 2024.
  • Revenues were $597.2 million for the first quarter of 2024 compared with $832.9 million for the same period last year.
  • The consolidated ethanol crush margin was ($9.3) million for the first quarter of 2024, compared with ($12.5) million for the same period in 2023.
  • Intersegment activities between the partnership and Green Plains Trade associated with terminal services transacted with the agribusiness and energy services segment will continue to be eliminated on a consolidated level.

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Retrieved on: 
torsdag, maj 2, 2024
Patient, Glycated hemoglobin, Research and development, Insulin, Blood, Research, Diabetes, C-peptide, Trial of the century, Osteopathic medicine in Canada, A1C, Administration, Type 2 diabetes, DSM-IV codes, Diagnosis, Glucose, Quantity, Cancer, Hypoglycemia, Pharmaceutical industry

Cash position of $145.3 million at the end of the first quarter of 2024

Key Points: 
  • Cash position of $145.3 million at the end of the first quarter of 2024
    REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported first quarter 2024 financial results and corporate highlights.
  • There is currently a waitlist for the fourth cohort which we expect will open for enrollment in the second half of this year.
  • This is truly an exciting and validating update on our progress in type 1 diabetes.
  • On track to announce a third development candidate from the Biomea FUSION™ Platform technology.

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

Retrieved on: 
onsdag, april 24, 2024
Urine, Kidney, FDA, Shanda, Embolism, Huber loss, Hepatic encephalopathy, Uric acid, Oliguria, Congestion, Blood volume, Furosemide, Organic acid, Deafness, Erythema, Cerebral edema, Ascites, Tinnitus, History, Thrombosis, Creatinine, NYHA, Dehydration, BUN, Patient, Hypersensitivity, Ototoxicity, Anuria, Glucose, Azotemia, Hypoproteinemia, CO2, Diuresis, Cirrhosis, Chronic kidney disease, Edema, Urinary retention, Bruise, Growth, Benign prostatic hyperplasia, Coma, Heart failure, Pharmaceutical industry

BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector.

Key Points: 
  • The auto-injector is being developed as a complement to the FDA approved On-body Infusor in an effort to provide patients with a subcutaneous injection and prescribers with treatment flexibility.
  • If approved, the Company believes the auto-injector also has the potential to meaningfully reduce manufacturing costs.
  • FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.
  • The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING

Retrieved on: 
tisdag, april 16, 2024
Pain, Electrode, SCS, Epidural space, Neurological disorder, Animal, Diabetes, CGM, Electricity, Doctor of Philosophy, Blood, PDN, Patient, Spinal cord stimulator, Spinal cord, Glucose, Hypoesthesia, Quality of life, Medical device

Rutherford, NJ, April 16, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural space. A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).

Key Points: 
  • A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).
  • Combining SCS and continuous glucose monitoring (CGM) could provide several possible advantages, such as simplifying device management for those patients.
  • This is the second application of Glucotrack’s technology for implantable continuous glucose monitoring, in addition to its development of a long-term Continuous Blood Glucose Monitoring (CBGM) system.
  • The results demonstrated the Glucotrack epidural glucose values closely tracked both the blood glucose and subcutaneous CGM values.

Glytec Announces Support for Landmark New CMS Measures to Improve Diabetes Reporting

Retrieved on: 
torsdag, april 18, 2024
FDA, Congress, Hyperglycemia, CMS, HHS, Diabetes, Insulin, News, Hospital, UC Davis Medical Center, AHRQ, Partnership, Agency, Software as a service, IQR, White, Blood, Hypoglycemia, Patient, United States Congress, Medicare, Glucose, Organization, UC, Medical device

BOSTON, April 18, 2024 /PRNewswire/ -- Glytec, whose industry leading SaaS platform empowers collaborative diabetes management and insulin dosing from the hospital to the home, announces a major step forward in its advocacy and partnership efforts to drive excellence in diabetes care and a commitment to enable hospitals and providers to measure and improve outcomes for patients.

Key Points: 
  • Recently, CMS proposed the addition of two new mandatory electronic clinical quality measures (eCQMs) related to Severe Hypoglycemia and Severe Hyperglycemia for the CY 2026 reporting period.
  • The proposed rule change issued on April 10, 2024, impacts hospitals through the Hospital Inpatient Quality Reporting (IQR) program.
  • We are proud to align with industry experts, partners, clients, and CMS in supporting measures to advance diabetes care, reduce health inequities, and move beyond antiquated, paper-based solutions."
  • The mandatory measures are related to glucose and diabetes management, which have been significant challenges for the healthcare industry.

PAREMINA Announces Asia Debut at Beautyworld Tokyo 2024 with Innovative Anti-Aging Solutions

Retrieved on: 
måndag, april 15, 2024
Collagen, Oxidative stress, Nature, CELL, MD, Research, Tokyo Big Sight, Elastin, Lipid metabolism, Science, Probiotic, NEO, Antioxidant, Glucose, Ageing, Longevity, Beauty

TOKYO, Japan, April 14, 2024 /PRNewswire-PRWeb/ -- PAREMINA, a distinguished leader with over 60 years of expertise in natural antioxidants and bioactive research for beauty care, is thrilled to reveal its Asia debut at the Beautyworld Japan Tokyo from May 13 to 15, 2024. It is set to introduce two nutrition supplement products, NEO CELL, and NEO METABOLIC, to the Asian market at this industry event held at Tokyo Big Sight.

Key Points: 
  • PAREMINA debuts in Asia at Beautyworld Tokyo 2024, introducing NEO CELL & NEO METABOLIC, showcasing their deep expertise in bioactives and antioxidants.
  • TOKYO, Japan, April 14, 2024 /PRNewswire-PRWeb/ -- PAREMINA, a distinguished leader with over 60 years of expertise in natural antioxidants and bioactive research for beauty care, is thrilled to reveal its Asia debut at the Beautyworld Japan Tokyo from May 13 to 15, 2024.
  • PAREMINA's participation in Beautyworld Tokyo marks a significant milestone in the company's journey, introducing its science-based anti-aging solutions to a new audience.
  • For more information about PAREMINA and its participation in Beautyworld Tokyo 2024, please visit http://www.paremina.com .

Solugen Breaks Ground on Bioforge™ Marshall Facility, Bolstering U.S. Biomanufacturing Capabilities

Retrieved on: 
torsdag, april 11, 2024
Glucose, Agriculture, Carbon dioxide, SMSU, Marshall Public Schools, Nature, Institute of technology, Sustainability, Partnership, Employment, Entrepreneurship, Senior, JCF, Commerce, KTA, Workforce, ADM, CO2, Economic development, Southwest Minnesota State University, Renewable energy

MARSHALL, Minn., April 11, 2024 /PRNewswire/ -- Solugen, a rapidly scaling climate technology company revolutionizing everyday chemicals, broke ground on its new state-of-the-art biomanufacturing facility today during a ceremony held in Marshall, Minn.

Key Points: 
  • MARSHALL, Minn., April 11, 2024 /PRNewswire/ -- Solugen, a rapidly scaling climate technology company revolutionizing everyday chemicals, broke ground on its new state-of-the-art biomanufacturing facility today during a ceremony held in Marshall, Minn.
  • The 500,000-square-foot Bioforge™ Marshall is being constructed on a 34-acre parcel adjacent to ADM's existing corn processing complex.
  • "Today's groundbreaking represents a key milestone in our growth journey, underscoring our commitment to innovation and the future of biomanufacturing in the U.S.," said Gaurab Chakrabarti, CEO and Co-Founder of Solugen.
  • "As a community deeply rooted in agriculture and innovation, we warmly welcome Solugen to Marshall," said City of Marshall Mayor Bob Byrnes.

Drinking apple cider vinegar may help with weight loss but its health benefits are overstated

Retrieved on: 
onsdag, april 10, 2024
Well, Research, Disease, Overweight, Health, Glucose, Diarrhea, Myocardial infarction, Apple, Cell, Serum, Infection, Appetite, Vegetable, Incidence, Acetic acid, Risk, Physiology, Lipid, Insulin, Diabetes, Weight loss, Internet, Stroke, Blood, Mortality, Cancer, Systematic review, Breakfast, Diet, Cholesterol, Vomiting, Drinking water, Dietary supplement

One day, she explained that she adds apple cider vinegar to improve my health.

Key Points: 
  • One day, she explained that she adds apple cider vinegar to improve my health.
  • Apple cider vinegar is a natural product made of fermented apple juice that has gone sour.
  • I decided to turn medical sleuth and investigate whether apple cider vinegar is as good for health as it sounds.

Claim: disinfectant properties

  • But does apple cider vinegar’s decontaminant qualities translate to the human gut?
  • Our stomachs produce acid, which acts as a natural barrier to infection, so how can adding more acid help?

Claim: weight loss and management of type 2 diabetes

  • There are plenty of anecdotal claims that apple cider vinegar can aid weight loss, supported by limited evidence from several small studies.
  • Apple cider vinegar is thought to cause weight loss through its effect on delay of gastric emptying.
  • Reduced calorific intake will lead to weight loss – but how are the metabolic effects on blood glucose and lipids mediated?
  • In type 2 diabetes there is a reduction in sensitivity to insulin which in turn leads to a reduced uptake of glucose by cells.

Claim: reduces risk of heart disease

  • Raised blood lipids are a risk factor for cardiovascular diseases such as myocardial infarction and stroke.
  • Well, I’m afraid there’s no scientific evidence that vinegar consumption of any kind reduces cardiovascular morbidity and mortality in those with or without diabetes.

Claim: cancer treatment and prevention

  • One of the more outrageous claims of benefits of daily apple cider vinegar consumption is that it may prevent or treat cancer.
  • A frequently quoted case-control study from China found that an increased consumption of vinegar was associated with a reduced incidence of oesophageal cancer.


Stephen Hughes does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.